Patients

Many of the pages within this Web site offer information on A rare, inherited, and sometimes fatal metabolic bone disease characterized by poor bone mineralization and profound skeletal defects.hypophosphatasia (HPP), information about A research study that uses consenting human subjects to test the safety and efficacy of new therapeutic interventions and diagnostic tests.clinical trials, and links to additional resources.

At Enobia, we recognize the challenges of living with HPP. We are focused on developing A subcutaneous enzyme replacement therapy with affinity for bone that is currently in clinical trials.ENB-0040, an investigational A molecule that catalyzes or triggers biochemical reactions.enzyme replacement therapy, which we hope will provide a new treatment option for patients with HPP.

ENB-0040 is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.